Logo
x

Search

Subscribe Now

Agios

Agios Entered into an Exclusive Worldwide License Agreement with Alnylam for siRNA to Treat Polycythemia Vera

Agios Entered into an Exclusive Worldwide License Agreement with Alnylam for siRNA to Treat Polycythemia Vera

  • August 4, 2023
Agios’ Pyrukynd (mitapivat) Receives the EC’s Marketing Authorization for the Treatment of Pyruvate Kinase (PK) Deficiency

Agios’ Pyrukynd (mitapivat) Receives the EC’s Marketing Authorization for the Treatment of Pyruvate Kinase (PK) Deficiency

  • November 10, 2022
Agios’ Pyrukynd (mitapivat) Receives EMA's CHMP Positive Opinion Recommending the Marketing Authorization for the Treatment of PK Deficiency

Agios’ Pyrukynd (mitapivat) Receives EMA's CHMP Positive Opinion Recommending the Marketing Authorization for the Treatment of PK...

  • September 16, 2022
Agios Publishes P-III (ACTIVATE-T) Study Results of Pyrukynd (mitapivat) for Pyruvate Kinase Deficiency in The Lancet Haematology

Agios Publishes P-III (ACTIVATE-T) Study Results of Pyrukynd (mitapivat) for Pyruvate Kinase Deficiency in The Lancet Haematology

  • August 19, 2022
Agios Presents Results of Pyrukynd (mitapivat) in P-III (ACTIVATE) Study for the Treatment of PK Deficiency at EHA 2022

Agios Presents Results of Pyrukynd (mitapivat) in P-III (ACTIVATE) Study for the Treatment of PK Deficiency at EHA 2022

  • June 13, 2022
Agios’ Pyrukynd (mitapivat) Receives the US FDA’s Approval as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with PK Deficiency

Agios’ Pyrukynd (mitapivat) Receives the US FDA’s Approval as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with...

  • February 21, 2022
Verrica Pharmaceuticals’ Ycanth (cantharidin) Topical Solution Receives the US FDA’s Approval for Pediatric and Adult Patients with Molluscum Contagiosum

    Verrica Pharmaceuticals’ Ycanth (cantharidin) Topical Solution Receives the US FDA’s Approval for Pediatric and Adult Patients wit...

    • July 24, 2023
    Insights+: EMA Marketing Authorization of New Drugs in November 2022

      Insights+: EMA Marketing Authorization of New Drugs in November 2022

      • December 28, 2022
      Agios’ Pyrukynd (mitapivat) Receives the EC’s Marketing Authorization for the Treatment of Pyruvate Kinase (PK) Deficiency

        Agios’ Pyrukynd (mitapivat) Receives the EC’s Marketing Authorization for the Treatment of Pyruvate Kinase (PK) Deficiency

        • November 10, 2022
        PharmaShots Weekly Snapshots (September 12 - 16, 2022)

          PharmaShots Weekly Snapshots (September 12 - 16, 2022)

          • September 16, 2022
          Agios’ Pyrukynd (mitapivat) Receives EMA

            Agios’ Pyrukynd (mitapivat) Receives EMA's CHMP Positive Opinion Recommending the Marketing Authorization for the Treatment of PK...

            • September 16, 2022
            PharmaShots Weekly Snapshots (August 15 - 19, 2022)

              PharmaShots Weekly Snapshots (August 15 - 19, 2022)

              • August 19, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.